The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2014TDO Inhibitors: A New Treatment Option for Parkinson’s Disease
Study Rationale:
Tryptophan-2,3-dioxygenase (TDO) is a key enzyme in the tryptophan degradation pathway. In a Parkinson’s disease (PD) model, TDO was identified as a potential... -
Research Grant, 2014PARK14-dependent SOCE and Sporadic Parkinson’s Disease
Objective/Rationale:
Mutations in the PARK14 gene are associated with Parkinson’s disease (PD), but its role in idiopathic PD is presently unknown. Recently we identified a role of PARK14... -
Target Validation, 2014Melanoma-related Gene as a Therapeutic Target for Parkinson's Disease
Objective/Rationale:
Individuals with Parkinson’s disease (PD) are more likely to develop melanoma. Conversely, melanoma patients are at higher risk of developing PD. This bidirectional link... -
Rapid Response Innovation Awards, 2014GSNOR Inhibition for Treatment of Parkinson’s Disease
Study Rationale:
Parkinson’s disease may be driven by inflammation and toxic, reactive products from oxygen metabolism. SAJE Pharma’s drugs target an enzyme called s... -
Rapid Response Innovation Awards, 2014Drug Rescue of PINK1: New Therapeutic Modality for Treating Parkinson’s Disease
Study Rationale:
Mitochondrial dysfunction has long been linked to Parkinson’s disease. We are investigating a class of drugs that increase the activity of an important mitochondrial quality... -
Rapid Response Innovation Awards, 2014Functional Characterization of HIP1R in Parkinson’s Disease
Study Rationale:
Intracellular vesicle trafficking is an important mechanism for delivering proteins to their proper location where they can function within cells. Various genes...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.